Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
COSTS AND EXPENSES:        
Research and development $ 2,333,058 $ 1,305,610 $ 6,365,868 $ 3,310,248
General and administrative 1,150,710 1,162,278 3,146,605 3,491,259
Total costs and expenses 3,483,768 2,467,888 9,512,473 6,801,507
LOSS FROM OPERATIONS (3,483,768) (2,467,888) (9,512,473) (6,801,507)
OTHER INCOME:        
Gain on revaluation of derivative warrants 9,100 177,912 16,625 3,201,004
Interest income, net 3,969 3,116 12,297 5,303
Total other income, net 13,069 181,028 28,922 3,206,307
NET LOSS $ (3,470,699) $ (2,286,860) $ (9,483,551) $ (3,595,200)
BASIC AND DILUTED NET LOSS PER COMMON SHARE $ (0.26) $ (0.43) $ (0.73) $ (1.02)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE 13,470,974 5,368,235 12,986,435 3,541,000